ABSTRACT
Medullary thyroid carcinoma (MTC) is a relatively uncommon tumor type, accounting for 5% or less of thyroid malignancies. 1 However, it warrants attention because it causes a disproportionate number of thyroid cancer deaths due to its more aggressive clinical behavior compared with well-differentiated papillary and follicular thyroid carcinomas. 2 Furthermore, the clinical management of MTC differs from nonmedullary thyroid carcinoma. Thus, accurate diagnosis is important so that patients can be appropriately treated.
Treatment is, in part, dictated by the unique molecular pathology of these tumors. A significant subset is hereditary, due to germline mutations in the RET proto-oncogene, and patients with MTC are routinely referred for genetic testing. [3] [4] [5] [6] Patients who are found to have hereditary disease can then be monitored for other associated endocrine Upon completion of this activity you will be able to:
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abnormalities, and at-risk family members can be screened and treated prior to the development of MTC (with prophylactic thyroidectomy). Somatic (nongermline) RET mutations also occur in a significant proportion of sporadic MTCs. 7 More recently, RAS mutations have been identified in RET wild-type sporadic tumors. 8 Genetic testing of tumor tissue for somatic mutations is not routinely performed since none of these alterations currently affects patient management. However, RET activation in these tumors has made it possible to use targeted therapy to treat advanced and metastatic MTC. 9, 10 It is possible that genetic testing of tumor tissue to predict response to a particular targeted agent, as is currently done for other cancer types such as colon and lung, may come into practice in the future. Our aim is to briefly review the pathologic features of MTC and then explore the molecular basis of both hereditary and sporadic disease. In addition, we address the role of diagnostic molecular testing to identify and manage hereditary cases, as well as the development of targeted therapies for treatment of both hereditary and sporadic tumors. Finally, the prospect of molecular testing of tumor tissue to predict response to therapy is explored.
Pathologic Features of MTC

Histopathology and Cytopathology
MTC is a neuroendocrine carcinoma that arises from the neural crest-derived parafollicular C cells. C cells are located in the upper one-third of the thyroid lobes bilaterally but cannot normally be seen on routine H&E sections because they are so infrequent and morphologically similar to the much more numerous follicular cells. Their function is to produce calcitonin, which has a poorly defined physiologic role. Calcitonin is, however, an important serum tumor marker for patients with MTC because it is also secreted by these tumors.
The typical MTC is solid with sheets or nests of cells that are plasmacytoid and have abundant pale pink cytoplasm and round to oval nuclei with granular chromatin ❚Image 1❚. Tumor cells are usually uniform but may show pleomorphism. Amyloid is present in approximately 80% of the tumors and is composed of calcitonin secreted by the tumor cells (Image 1). 11 On fine-needle aspiration biopsy, the cells are usually singly dispersed or loosely cohesive, and red cytoplasmic granules may be present (Diff-Quik stain). The amyloid may resemble the dense colloid that is often seen in cytologic preparations of papillary thyroid carcinomas. However, amyloid, unlike colloid, may be metachromatic on Diff-Quik-stained slides. Hereditary tumors are more often multifocal than sporadic tumors but otherwise do not have distinctive histologic or cytologic features.
MTCs can have a wide variety of divergent histologic patterns. Described histologic variants include spindle cell, papillary or pseudopapillary, follicular or glandular, clear cell, oncocytic, mucin producing, melanin producing, paraganglioma-like, and small cell, among others. In some cases, these variants may mimic other types of thyroid carcinomas or lesions ❚Image 2❚. For example, the follicular variant can resemble follicular carcinoma or adenoma when it has a capsule or even nodular hyperplasia when it lacks a capsule. Benign entrapped thyroid follicles may also be present within the tumor, and this should not be mistaken as evidence of follicular differentiation. Similarly, the papillary or pseudopapillary variant may raise the possibility of papillary thyroid carcinoma. Although intranuclear cytoplasmic pseudoinclusions and nuclear contour irregularity may be seen in MTC, other cytologic features are usually present that are not typical of papillary thyroid carcinoma (plasmacytoid cells with pale pink cytoplasm and granular chromatin).
Other entities in the differential diagnosis include metastatic renal cell carcinoma for the clear cell variant, metastatic melanoma for the melanin-producing variant, and paraganglioma for the paraganglioma-like variant. Metastasis to the thyroid gland should also be considered when the small cell variant is encountered. Because of the wide variety of histologic patterns that have been reported, it is important to have a low threshold for performing immunohistochemistry in any thyroid tumor that lacks definite colloid or is simply not typical of another type of thyroid carcinoma. Useful positive immunostains include calcitonin and monoclonal carcinoembryonic antigen, which are negative in other thyroid tumors. Calcitonin, ❚Image 2❚ Select variants of medullary thyroid carcinoma (MTC) that can mimic other thyroid lesions. A, Low-power image of a follicular variant that has variably sized cystic spaces filled with colloid-like material and that resembles nodular hyperplasia (H&E, ×20). B, High-power image of the same follicular variant MTC that has "scalloping" at the periphery of the colloid-like material within pseudofollicles. The tumor cells, however, have a pale pink cytoplasm and a plasmacytoid appearance typical of MTC (H&E, ×40). C, A papillary or pseudopapillary variant of MTC that has finger-like projections with fibrovascular cores (H&E, ×40). D, Intranuclear pseudoinclusions may occasionally be seen in MTC as well (arrow) (H&E, ×60).
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however, is not specific to MTC and can be positive in neuroendocrine carcinomas from other organ systems. 12 If material for immunohistochemistry is not available on fineneedle aspiration biopsy but is felt to be needed, one can request that the clinician check a serum calcitonin level, since it is almost always elevated in patients with MTC.
C-Cell Hyperplasia
Histologically recognizable C-cell hyperplasia is generally considered a neoplastic process and a precursor lesion to MTC (neoplastic C-cell hyperplasia). It is characterized by nodular aggregates of C cells that are enlarged and have more abundant pale pink to clear cytoplasm than the adjacent follicular cells and often granular chromatin ❚Image 3❚. The cells encircle thyroid follicles and are confined by basement membrane. Stromal fibrosis should not be present since this is a sign of invasion (medullary thyroid microcarcinoma). Calcitonin immunohistochemistry can be used to highlight the foci of C-cell hyperplasia: greater than 50 C cells per low-power (×100) field should be seen to make this diagnosis. 13 Neoplastic C-cell hyperplasia is commonly present in patients with hereditary tumors but also occasionally occurs adjacent to sporadic tumors or even incidentally in thyroids removed for other reasons. C-cell hyperplasia should be noted when identified on routine H&E sections since it represents an indication for genetic testing (see below). 14 Neoplastic C-cell hyperplasia is not, however, diagnostic of hereditary disease. When C-cell hyperplasia is not visible on routine H&E sections (because the C cells are not atypical and are therefore indistinguishable from adjacent follicular cells), it should be considered reactive, rather than neoplastic, C-cell hyperplasia. In such cases, C-cell hyperplasia is only seen by calcitonin immunohistochemistry. The distinction between reactive C-cell hyperplasia and neoplastic C-cell hyperplasia may be difficult in some cases. When there is uncertainty, genetic testing for a constitutional RET mutation can exclude hereditary disease.
Hereditary vs Sporadic Disease
Approximately 25% of MTCs are hereditary. 15 The hereditary cases occur in the setting of three syndromes: multiple endocrine neoplasia syndrome (MEN) type 2A (MEN2A), MEN type 2B (MEN2B), and familial medullary thyroid carcinoma syndrome (FMTC). These syndromes are autosomal dominant and highly penetrant; virtually all patients will develop MTCs if their thyroid glands are not removed. 16 MEN2B is the least common (~5% of hereditary MTC), and patients develop carcinomas at the youngest age, often before 10 years. Both MEN2A and MEN2B syndromes are associated with other endocrine abnormalities and clinical features (these are summarized in ❚Table 1❚). Pheochromocytoma is seen in about half of patients with MEN2A and MEN2B. 16 A subset of patients with MEN2A develop parathyroid hyperplasia, which is not seen in MEN2B. 16 Patients with MEN2B have a marfanoid habitus, ocular abnormalities, mucosal neuromas, and gastrointestinal ganglioneuromatosis. Patients with FMTC do not have other associated features. However, it is thought that FMTC represents a mild variant of MEN2A with low penetrance of pheochromocytoma and hyperparathyroidism. If pheochromocytoma or hyperparathyroidism is seen in a family with FMTC, reclassification as MEN2A is warranted.
Sporadic tumors usually occur in the fifth to sixth decades of life and lack other associated MEN features or family history of MTC. There is overlap between the age of presentation of MTCs in sporadic and hereditary cases. In fact, approximately 5% to 10% of patients with apparently sporadic tumors (no family history or stigmata of an MEN syndrome) have hereditary disease (FMTC or MEN2A) upon genetic testing. 17 The initial clinical management of both hereditary and sporadic MTC is the same but is different from that of follicular-derived thyroid tumors. All patients with a fine-needle aspiration biopsy or serum calcitonin level diagnostic or suspicious for MTC will be screened for MEN-associated diseases (pheochromocytoma and hyperparathyroidism) prior to thyroid surgery unless the patient has already undergone ❚Image 3❚ C-cell hyperplasia is characterized by nodular aggregates of C cells that have more abundant pale pink cytoplasm than the adjacent follicular cells and often granular chromatin (H&E, ×40). Stromal fibrosis is absent and, if present, suggests an invasive microcarcinoma.
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© American Society for Clinical Pathology genetic testing and has a negative family history. 14 If a pheochromocytoma is identified, it should be treated first to avoid a hypertensive crisis. If preoperative serum calcitonin is high (>400 pg/mL) or there is nodal disease on imaging, the patient will be evaluated for distant metastases. 14 Surgery typically consists of total thyroidectomy and prophylactic central (level VI) lymph node dissection for clinically detected organ-confined disease. 14 
Molecular Basis of Hereditary Disease and Genotype-Phenotype Correlation
In the early 1990s, activating mutations in the Rearranged during Transfection, or RET, proto-oncogene were identified as the genetic basis for MEN2A, MEN2B, and FMTC syndromes. [3] [4] [5] [6] Since then, germline RET mutations have been identified in 98% of patients with MEN2A, 95% of patients with MEN2B, and 88% of patients with FMTC. 18 RET is located on chromosomal band 10q11.2 and encodes a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the parathyroids, urogenital system, and neural crest-including brain, para-and sympathetic ganglia, adrenal medulla, enteric ganglia, and thyroid C cells. 19 Not surprisingly, many of these organ systems are affected in the MEN syndromes with the notable exceptions of the brain and urogenital system.
More than 80 different RET mutations in exons 5, 8, 10, 11, 12 to 16, and 19 have been associated with hereditary MTC. 20 Most are single-nucleotide missense mutations, and all lead to constitutive activation of the RET tyrosine kinase and downstream signaling pathways. A database of RET mutations, including variants of unknown significance, is maintained at the University of Utah/ARUP Laboratories (http:// www.arup.utah.edu/database/MEN2/MEN2_welcome.php). 20 The RET gene also harbors several common polymorphisms, benign genetic variants that should not be overinterpreted as causes of familial cancer (eg, G691S, which is present in as many as one in five healthy individuals). 21 In general, if a RET variant is detected by sequencing, particularly at a noncanonical position, it is important to consult a database of common polymorphisms, such as the Single Nucleotide Polymorphism Database (http://www. ncbi.nlm.nih.gov/SNP/) or the Exome Variant Server from the National Institutes of Health's National Heart, Lung, and Blood Institute (http://evs.gs.washington.edu/EVS/), to search for evidence that the variant may be a polymorphism without significance.
The specific location of the mutations within the RET gene is likely responsible for the different constellation of phenotypes in each hereditary syndrome ❚Figure 1❚. The RET protein has an extracellular domain composed of a cadherin-like region that is important for ligand binding and a highly conserved cysteine-rich domain. The intracellular region contains two tyrosine kinase domains (TK1 and TK2). Upon ligand binding, the extracellular cysteine-rich domain facilitates receptor dimerization, which leads to autophosphorylation and activation of the intracellular TK1 and TK2. This activates multiple signaling pathways, including RAS/ RAF/MAP kinase, PI3K/AKT, and STAT3, that lead to cell survival, proliferation, migration, and differentiation. Several RET mutations give rise to MEN2A syndrome, the majority of which are located in cysteines within the extracellular cysteine-rich domain (corresponding to exons 10 and 11). 22 These mutations abolish intramolecular disulfide bridge formation and allow for constitutive dimerization of two RET proteins in the absence of ligand. 23 Other mutations in exons 13, 14, and, rarely, 5, 8, 12, 15, and 19 have also been reported in MEN2A. 20, 22 Thirty-nine different mutations have been associated with FMTC in exons 5, 8, 10, 11, and 13 to 16, with most being located in the cysteinerich domain or TK1 domain. 18 There is overlap between the mutations that are associated with MEN2A and FMTC. Some mutations can be associated with either MEN2A or FMTC in different families, which is why FMTC is considered a variant of MEN2A. The mutations that can give rise to either syndrome are associated with low penetrance of pheochromocytoma and hyperparathyroidism.
In contrast to the diversity of mutations seen in MEN2A/ FMTC, 95% of patients with MEN2B have a single mutation in exon 16 (M918T) that causes a conformational change in the intracellular TK2 binding pocket and allows for constitutive kinase activation in the absence of dimerization, as well as altered substrate binding. 23, 24 Much less commonly (2%-3% of cases), MEN2B is caused by a dinucleotide substitution in codon 883 (exon 15) in the TK1 domain. 25 Very rarely, simultaneous mutations in two different codons (eg, V804M/E805K mutated in cis) can cause an MEN2B-like phenotype ("atypical" MEN2B). 26 It is thought that the different mechanisms of RET activation induced by these mutations trigger different patterns of phosphorylation and cell signaling. For example, the M918T codon mutation that accounts for the vast majority of MEN2B is associated with increased PI3K/AKT pathway activation compared with MEN2A-associated mutations. 27, 28 This may explain differences in disease phenotype among the syndromes. Since some mutations are associated with either MEN2A or FMTC in a given family, there are likely additional modifying factors that affect phenotype as well.
Furthermore, within each of the hereditary syndromes, the specific RET mutation is associated with variation in disease phenotype. In MEN2A, the specific codon mutated roughly correlates with the age of presentation with MTC and the probability of developing pheochromocytoma or hyperparathyroidism. Codon 634 in exon 11, corresponding to a cysteine in the extracellular cysteine-rich domain, is the most commonly altered codon in MEN2A. Mutations at codon 634 are associated with the earliest onset of MTC, often before age 20 years, and the highest risk of pheochromocytoma and hyperparathyroidism in this syndrome. 24, 29, 30 In addition, cutaneous lichen amyloidosis is almost exclusively seen in patients with codon 634 mutations. Hirschsprung disease, a genetically heterogeneous disease, can co-occur with MTC in patients with mutations in exon 10. 31, 32 The M918T mutation that accounts for 95% of MEN2B cases is associated with the earliest onset of MTC of any RET mutation, in some cases within the first year of life. 30 In addition, the tumors are more aggressive and typically present at a more advanced stage. 33 MEN2B patients with the less common A883F mutations appear to develop MTCs at an older age and have less aggressive tumors compared with those with M918T. 25 The rare "atypical" MEN2B syndrome caused by simultaneous mutations in two different codons has also been associated with a more mild phenotype. 26, 34 In FMTC, those mutations not involving the cysteinerich domain (usually in exon 13, 14, or 15) are associated with the latest onset of MTC. 35 This group of mutations shows significant clinical overlap with the age of onset of sporadic MTC. Therefore, routine genetic screening of patients with apparently sporadic disease may reveal unexpected germline mutations in a subset of cases, usually in patients with de novo and/or noncysteine mutations. 17 
Diagnostic Molecular Testing for Hereditary Disease
The American Thyroid Association (ATA) recommends that all patients with a personal history of MTC, primary C-cell hyperplasia, or clinical features of MEN2 or FMTC should be offered genetic testing for germline RET mutations. 14 Furthermore, anyone with a family history of MEN2 or FMTC in a first-degree relative should also undergo genetic testing. 14 The rationale for screening all patients with MTC or C-cell hyperplasia is based on the evidence that approximately 5% to 10% of patients with MTC who lack clinical features to suggest hereditary disease will harbor a germline RET mutation, often de novo and/or noncysteine mutations (as described above). 17 Screening of at-risk family members should also be emphasized since those family members found to harbor a RET mutation can be treated with prophylactic thyroidectomy before carcinoma develops and be monitored for pheochromocytoma or hyperparathyroidism, if indicated for the specific mutation identified. Although de novo mutations are common in MEN2B, only 5% to 10% of MEN2A/FMTC cases represent new mutations. 36, 37 Therefore, siblings and even parents may be at risk in addition to children of the index case. The ATA has guidelines for the age of recommended prophylactic thyroidectomy in mutation carriers based on the specific RET mutation ❚Table 2❚.
Approximately 60 laboratories in the United States perform constitutional genetic testing for RET mutations on peripheral blood (www.ncbi.nlm.nih.gov/gtr). However, the DOI: 10.1309/AJCPHWACTTUYJ7DD
© American Society for Clinical Pathology laboratories vary in methodology, with a few laboratories sequencing the entire coding region, and the majority select exons. Laboratories that perform sequencing of select exons also vary in which specific exons are sequenced. Most laboratories routinely sequence exons 10, 11, 13, and 14 (cysteine-rich and TK1 domains) to exclude MEN2A/FMTC. Some also sequence exons 15 and 16 and rarely exons 5 and 8. It is helpful to know which exons an individual laboratory sequences. For example, it may be important for patients with apparently sporadic MTC undergoing genetic screening to have sequencing that includes the noncysteine region (especially codons 13, 14, and 15), since these regions are most likely to harbor unexpected germline mutations in this patient population. 17 For those with apparently sporadic MTC or suspected MEN2A/FMTC, the ATA recommends that initial testing should include sequencing of MEN2-specific exons but does not specify the exons that should be included. 14 Sequencing of the entire coding region of RET is recommend only for those who meet clinical criteria for MEN2 but in whom initial select exon sequencing was negative. 14 For patients with suspected MEN2B or those at risk for a known mutation (due to a kindred with a known RET mutation), genetic testing is more straightforward. Patients with suspected MEN2B (usually identified by their characteristic clinical features) can be specifically tested for the M918T mutation, present in 95% of cases, with additional testing for rare MEN2B-associated mutations only if the M918T mutation is not found. Furthermore, the ATA recommends sequencing the entire coding region of RET for patients who meet clinical criteria for MEN2B but in whom testing for known mutations is negative. 14 Patients with a kindred harboring a known RET mutation can be specifically tested for that mutation.
Molecular Basis of Sporadic Disease
While patients with sporadic MTC do not harbor germline RET mutations, up to half have somatic RET mutations in their tumors. 7 The M918T mutation (seen in most patients with MEN2B) is also the most common mutation in sporadic tumors, accounting for 75% to 95% of RET mutations. 7 Many other RET mutations have been reported in sporadic tumors, including in exons 10, 11, 15, and 16. 7 As in MEN2B, M918T mutations are associated with more aggressive/advanced stage disease in sporadic tumors. 38 Somewhat surprisingly, RET mutations in sporadic tumors may not necessarily drive tumorigenesis but rather appear important for progression of disease. This is supported by the fact that RET mutations are present in a lower proportion of sporadic microcarcinomas than of larger tumors and, when present, often show mutational heterogeneity, even in advanced disease. 39, 40 This means that RET mutations may be found in subpopulations of tumor cells rather than the entire tumor, indicating that the mutation arose later in the course of disease. Indeed, in half of patients with RET mutations and multiple metastases, the mutation was found in some but not all metastatic deposits ❚Figure 2❚. 39 Much more recently, activating RAS mutations have also been identified in a subset of sporadic MTCs. These mutations may be associated with clinically less aggressive tumors. 8, 41 Mutations occur within known hotspots in exons 2, 3, and 4 and predominantly involve HRAS and KRAS. 42 ❚Figure 2❚ RET mutational heterogeneity has been reported in sporadic tumors harboring somatic mutations. This means that a subset of tumor cells may harbor a RET mutation that is not present throughout the entire tumor and may be present in some but not all metastases.
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are rare. 41 RAS mutations appear to be almost always mutually exclusive with RET mutations and are present in approximately 10% to 45% of RET wild-type sporadic tumors. 8, [41] [42] [43] This leaves a small group of RET and RAS mutation-negative tumors for which the main genetic changes are undefined. It is important to note that the RAS signaling pathway is activated by the RET tyrosine kinase receptor. Therefore, activation of this pathway, either by RET or RAS mutation, appears important in both hereditary and sporadic tumors.
Molecular Targeted Therapy
Molecular targeted therapy for MTC has been long sought due to significant shortcomings of traditional treatment strategies with a lack of effective systemic therapy. Conventional chemotherapy is of limited benefit and associated with significant toxicity. Radioactive iodine is not useful because MTC is not derived from thyroid follicular cells and therefore does not take up iodine. Currently, complete surgical resection (thyroidectomy and lymph node dissection) is the only chance for cure. However, about half of patients have lymph node metastases, and only 10% of these cases are cured by surgery. 44 A subset of patients have an indolent clinical course despite incurable disease. Long-term, 10-year survival is more than 90% for those with localized disease, decreasing to 78% and 40% in patients with regional and distant metastases, respectively. 45 Nevertheless, there is a need for additional treatment modalities in patients who have residual or recurrent disease after surgery.
In the past several years, two targeted tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved by the US Food and Drug Administration for the treatment of symptomatic, advanced, or progressive MTC. This approval was based on the results of two large phase III clinical trials that showed increased progression-free survival of each drug compared with placebo. 9, 10 Both of these TKIs are nonselective and target multiple kinases in addition to RET. Vandetanib also targets VEGFR2, VEGFR3, and EGFR, while cabozantinib additionally targets c-MET and VEGFR2. It is thought that the efficacy of these drugs results in part from their ability to target multiple kinases. Unfortunately, both TKIs induce partial responses with resistance eventually developing, and an increase in overall survival has not yet been shown. 9, 10 Furthermore, since the design of the two phase III clinical trials was not identical and the two drugs were not compared head to head, it is difficult to determine which drug is more effective. 9, 10 However, the side effect profile for each is different and may be considered when selecting a treatment option. The most significant side effect associated with vandetanib is QT interval prolongation with rare torsades de pointes and sudden death; with cabozantinib, the side effects are rare fistula formation, gastrointestinal perforation, and hemorrhage. 9, 10 Nevertheless, these TKIs represent a significant advance in the treatment of MTC, and it seems likely that in the future, they will be a part of multidrug therapy.
One question that has been raised by the advent of TKIs for the treatment of MTC is whether RET and RAS mutation status affects tumor response to the drug. As of yet, this question has not been fully answered, but there is some evidence that mutation status may affect treatment response. In the phase III clinical trial of vandetanib, RET mutation status was unavailable or incomplete in nearly half (45.3%) of patients with sporadic tumors, so much is unknown about drug response by mutation status. 10 Nevertheless, M918T-mutated tumors (seen in MEN2B and the majority of RET mutationpositive sporadic tumors) appeared to have increased sensitivity to the drug (overall response rate of 54.5% vs 30.9%). 10 In vitro studies have also shown that V804M and V804L RET mutations conferred resistance to vandetinib. 46 All RET mutation subgroups, including RET mutation-negative tumors, showed benefit in the cabozantinib clinical trial, although the benefit was marginal in the RET-negative group and best in the M918T codon mutation group. 9, 47 Clearly, further data are needed to address response by particular RET mutation.
TKI response by RAS mutation status was not assessed initially in either clinical trial, likely because the discovery of RAS mutations in MTC was relatively recent. Subsequent analysis of a subgroup of RAS-mutated tumors showed comparable, although slightly shorter, progression-free survival with cabozantinib treatment than for RET-mutated tumors. 47 However, because RAS mutations have been associated with resistance to TKI therapy in other types of tumors, such as colon and lung cancer, a more thorough investigation in MTC is warranted. 48, 49 Although there is some evidence to suggest that TKI response varies by mutation status, additional information is needed. With more data, it is possible that RET and/or RAS mutation analysis of tumor tissue from formalin-fixed, paraffin-embedded blocks or fine-needle aspiration biopsy specimens for somatic mutations may become part of clinical practice in the future. If this is the case, several issues should be considered. One is the reported mutational heterogeneity that can be seen with RET mutations in sporadic tumors. 39 Caution should be exercised when RET mutation analysis is performed on a primary tumor in a patient being treated for metastatic disease, since the mutation status may be different in the metastasis. Another consideration is the method of testing, since next-generation sequencing may have higher sensitivity than Sanger sequencing 50 and allows several genes to be assayed on the same platform. The relative cost and effectiveness of these two methods should be considered before testing guidelines are established. 
Conclusion
In summary, molecular diagnostic testing has been a mainstay of the clinical management of MTC for many years. Patients are routinely referred for RET mutation analysis of constitutional DNA to identify hereditary cases so that they can be monitored for other associated endocrine abnormalities, and at-risk family members can be screened and treated prior to the development of MTC (with prophylactic thyroidectomy). Somatic (nongermline) mutations in either RET or RAS also occur in most sporadic MTCs. However, genetic testing of tumor tissue for somatic mutations is not routinely performed. It is possible that, with the advent of TKIs now in use to treat advanced and metastatic MTC, genetic testing of tumor tissue to predict response to a particular drug may come into practice in the future. However, further information about the impact of RET and RAS mutations on TKI treatment response is needed.
